Features of the Lipid Profile in Different Activity of the Components of the Renin-angiotenzin-aldosterone System in Patients with Essential Hypertention and Obesity


М. М. Кочуєва
В. Г. Псарьова
Н. М. Кириченко
Л. А. Рубан
Г. І. Кочуєв
А. С. Шалімова


The objective: the aim of the study was to evaluate the features of the lipid profile in the case of different activity of the components of the renin-angiotensin-aldosterone system in patients with arterial hypertension (AH) and concomitant obesity.

Materials and methods.188 patients with essential hypertension (EH) and obesity I–II degrees were examined (who gave informed written consent to participate in the study and met the inclusion criteria). The control group consisted of 25 practically healthy individuals, matched by age and sex with the main group patients.

Results. It was established that in patients with comorbidity of EH and obesity I–II degrees, the low-renin AH (LRAH) was found in 9,4% of cases. The LRAH and high-renin AH (HRAH) in obese patients did not differ in anthropometric indices.

Conclusion. In the presence of LRAH in patients with obesity I–II degrees the levels of atherogenic lipoproteins were significantly lower than in HRAH.


How to Cite
Кочуєва, М. М., Псарьова, В. Г., Кириченко, Н. М., Рубан, Л. А., Кочуєв, Г. І., & Шалімова, А. С. (2019). Features of the Lipid Profile in Different Activity of the Components of the Renin-angiotenzin-aldosterone System in Patients with Essential Hypertention and Obesity. Family Medicine, (2), 80–83. https://doi.org/10.30841/2307-5112.2.2019.175181


Pizoń T. The role of renin-angiotensin-aldosterone system in etiology and pathogenesis of arterial hypertension and its systemic complications – what remains from Laragh and Alderman idea? / T. Pizoń, M. Rajzer, T. Kameczura // Arterial Hypertension. – 2011. – Vol. 15. – P. 371–382.

Ferrario C.M. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease / C.M. Ferrario, W.B. Strawn // Am J Cardiol. – 2006. – Vol. 98. – P. 121–128.

Funder J.W. Aldosterone: A cardiovascular risk factor? / J.W. Funder, M. Reincke // Biochim Biophys Acta. – 2010. – Vol. 1802. – P. 1188–1192.

Marney A.M. Aldosterone and end-organ damage / A.M. Marney, N.J. Brown // Clin Sci. – 2007. – Vol. 113. – P. 267–278.

The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance / L. Ramalingam, K. Menikdiwela, M. LeMieux et al. // Biochim Biophys Acta Mol Basis Dis. – 2017. – Vol. 1863. – P. 1106–1114.

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men / G. Nickenig, A.T. Baumer, Y. Temur et al. // Circulation. – 1999. – Vol. 100. – P. 2131–2134.

Role of angiotensin II in hepatic inflammation through MAPK pathway: a review / M.M. Mohib, I. Hasan, W.K. Chowdhury et al. // J Hep. – 2016. – Vol. 2. – P. 1–8.

Renin angiotensin system in liver diseases: Friend or foe? / A.C. Simões e Silva, A.S. Miranda, N.P. Rocha et al. // World J Gastroenterol. – 2017. – Vol. 23. – P. 3396–3406.

Oral formulation of angiotensin-(1–7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice / J.D. Feltenberger, J.M. Andrade, A. Paraíso et al. // Hypertension. – 2013. – Vol. 62. – P. 324–330.

Yvan-Charvet L. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity / L. Yvan-Charvet, A. Quignard-Boulangé // Kidney Int. – 2011. – Vol. 79. – P. 162–168.

The relationship between plasma renin activity and serum lipid profiles in patients with primary arterial hypertension // T. Pizoń, M. Rajzer, W. Wojciechowska et al. Journal of the Renin-Angiotensin-Aldosterone System. – 2018. – Vol. Oct.-Dec. – P. 1–8.

Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter / M. Kaplan, M. Avirama, C. Knop et al. // Biochem Biophys Res Commun. – 2002. – Vol. 290. – P. 1529–1534.

Mazzolai L. The renin-angiotensin system and atherosclerosis / L. Mazzolai, D. Hayoz // Curr Hypertens Rep. – 2006. – Vol. 8. – P. 47–53.

Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells / J. Ni, K.-L. Ma, C.-X. Wang et al. // Lipids Health Dis. – 2013. – Vol. 12. – P. 49.

Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure / C. Borghi, M. Veronesi, E. Cosentino et al. // J Hypertens. – 2007. – Vol. 25. – P. 2051–2057.

(Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis / L. Ren, Y. Sun, H. Lu et al. // Circ Res. – 2018. – Vol. 122. – P. 730–741.

Identification of the (pro)renin receptor as a novel regulator of low-density lipoprotein metabolism / X. Lu, M.E. Meima, J.K. Nelson et al. // Circ Res. – 2016. – Vol. 118. – P. 222–229.

Strong A. (Pro)renin receptor and LDL clearance. An old player joins a new game / A. Strong, K. Musunuru // Circ Res. – 2016. – Vol. 118. – P. 187–189.

Physiological aldosterone concentrations are associated with alterations of lipid metabolism: observations from the general population / M. Hannich, H. Wallaschofski, M. Nauck et al. // Int J Endocrinol. – 2018. – Vol. 2018. – P. 4128174.

Plasma renin and outcome in the community: data from PREVEND / R.A. De Boer, N.F. Schroten, S.J. Bakker et al. // Eur Heart J. – 2012. – Vol. 33. – P. 2351–2359.

Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study / S. Verma, M. Gupta, D.T. Holmes et al. // Eur Heart J. – 2011. – Vol. 32. – P. 2135–2142.

Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study / N.I. Parikh, P. Gona, M.G. Larson et al. // Eur Heart J. – 2007. – Vol. 28. – P. 2644–2652.